Afuco™ Anti-MMP9 ADCC Therapeutic Antibody (Andecaliximab), ADCC Enhanced

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to MMP9. Andecaliximab is a human monoclonal antibody that can be potentially used in the treatment of Crohn's disease (CD), Colitis, ulcerative (UC), Solid tumors.
Supplier Creative Biolabs
Product # AFC-TAB-002ML
Pricing Inquiry
Host Human
Target MMP9
Species Reactivity Human
Type ADCC enhanced antibody
Applications ELISA, IHC, FC, IP, IF, FuncS
Storage Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Feedback